TORONTO, Canada, July 15, 2026
Cumulus Neuroscience has presented new clinical findings at the Alzheimer’s Association International Conference (AAIC) 2026, demonstrating that its NeuLogiq® Platform and Symbol Swap digital cognitive assessment can match or outperform traditional clinical benchmarks for identifying participants suitable for Alzheimer’s disease clinical trials. The data, presented across three independent studies, showed that the two-minute tablet-based Symbol Swap task accurately differentiated healthy controls, individuals with mild cognitive impairment (MCI), and patients with Alzheimer’s dementia, while also detecting blood biomarker-defined Alzheimer’s pathology in clinically normal individuals. The findings position the AI-powered digital biomarker platform as a promising solution for improving trial recruitment, reducing screen failures, and accelerating the development of next-generation Alzheimer’s therapies. By replacing lengthy cognitive assessments with a rapid, automated digital task, the technology has the potential to transform how researchers identify eligible participants for large-scale neurodegenerative disease studies while reducing both patient burden and operational costs.
Digital Cognitive Test Matches Leading Clinical Assessments
The featured Symbol Swap assessment is a two-minute digital implementation of the established Digit Symbol Substitution Test, designed to evaluate executive function using an intuitive tablet-based interface. Results presented at AAIC 2026 demonstrated that Symbol Swap achieved diagnostic performance comparable to or exceeding widely used cognitive screening tools, including the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Montreal Cognitive Assessment (MoCA), and Mini-Mental State Examination (MMSE). Importantly, the digital task demonstrated strong correlations with plasma phosphorylated tau-217 (pTau-217), a key blood biomarker associated with Alzheimer’s disease pathology, including among participants who appeared cognitively normal during conventional testing. The technology was evaluated through the CNS-101 home-based validation study, the Fastball i4i clinical investigation, and the multinational Global Alzheimer’s Platform (GAP) BioHermes-2 study, collectively highlighting its potential to serve as an efficient first-line digital screening tool before more expensive biomarker, PET imaging, or cerebrospinal fluid testing. The automated scoring system further supports consistent evaluation across decentralized and multi-site clinical trials.
NeuLogiq Platform Could Accelerate Alzheimer’s Drug Development
A second presentation at AAIC 2026 highlighted the broader capabilities of the NeuLogiq® Platform, demonstrating that its combined digital cognitive assessments and electroencephalography (EEG) biomarkers were well tolerated by study participants and sufficiently sensitive to detect meaningful neurological changes throughout Alzheimer’s disease progression. Researchers indicated that these digital endpoints could enable smaller, faster, and more efficient clinical trials, reducing development costs while improving participant experience. Company executives emphasized that one of the greatest challenges in Alzheimer’s drug development remains identifying biomarker-positive participants early enough to accelerate enrollment.
Advertisement
By integrating AI-powered digital cognition testing, remote monitoring, and multi-domain neurological biomarkers, the NeuLogiq Platform offers pharmaceutical companies a scalable solution for decentralized clinical trials conducted both at home and in clinical settings. Designed in collaboration with 10 leading global pharmaceutical companies, the platform is already supporting therapeutic development programs targeting Alzheimer’s disease, depression, and schizophrenia. The latest AAIC findings reinforce the growing role of digital biomarkers, artificial intelligence, and precision neurology in modern clinical research, positioning Cumulus Neuroscience at the forefront of innovations that could significantly shorten clinical trial timelines while improving recruitment efficiency and accelerating the development of urgently needed treatments for neurodegenerative disorders worldwide.
Source: Cumulus Neuroscience press release
